Lagercrantz (Q4 initial take): Continues to deliver with surgical precision - Redeye
Bildkälla: Stockfoto

Lagercrantz (Q4 initial take): Continues to deliver with surgical precision - Redeye

Redeye provides its initial take on Lagercrantz’s Q4 2025/2026 report, which beat our sales and EBITA estimates by 2% and 6%, respectively. The company sees good demand, especially within electrification, infrastructure, security, defense, and industrial niche products, which explains the 6% organic growth in the quarter. In addition, it has not yet seen any significant effects from the geopolitical situation.

Redeye provides its initial take on Lagercrantz’s Q4 2025/2026 report, which beat our sales and EBITA estimates by 2% and 6%, respectively. The company sees good demand, especially within electrification, infrastructure, security, defense, and industrial niche products, which explains the 6% organic growth in the quarter. In addition, it has not yet seen any significant effects from the geopolitical situation.
Börsvärldens nyhetsbrev